Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Gamma Secretase (EC 3.4.23.46) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Gamma Secretase (EC 3.4.23.46) Products under Development by Stage of Development | 9 | 1 |
| Gamma Secretase (EC 3.4.23.46) Products under Development by Therapy Area | 10 | 1 |
| Gamma Secretase (EC 3.4.23.46) Products under Development by Indication | 11 | 1 |
| Gamma Secretase (EC 3.4.23.46) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Gamma Secretase (EC 3.4.23.46) Products under Development by Companies | 14 | 2 |
| Gamma Secretase (EC 3.4.23.46) Products under Development by Universities/Institutes | 16 | 2 |
| Gamma Secretase (EC 3.4.23.46) Therapeutics Assessment | 18 | 5 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 1 |
| Assessment by Molecule Type | 22 | 1 |
| Gamma Secretase (EC 3.4.23.46) Companies Involved in Therapeutics Development | 23 | 13 |
| Amgen Inc. | 23 | 1 |
| Astellas Pharma Inc. | 24 | 1 |
| Bristol-Myers Squibb Company | 25 | 1 |
| Critical Outcome Technologies Inc. | 26 | 1 |
| FORUM Pharmaceuticals Inc. | 27 | 1 |
| Humanetics Corporation | 28 | 1 |
| Lipopharma Therapeutics SL | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| NeuroGenetic Pharmaceuticals, Inc. | 31 | 1 |
| Pfizer Inc. | 32 | 1 |
| Stemline Therapeutics, Inc. | 33 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 34 | 1 |
| Takeda Pharmaceutical Company Limited | 35 | 1 |
| Gamma Secretase (EC 3.4.23.46) Drug Profiles | 36 | 28 |
| AS-2715348 Drug Profile | 36 | 1 |
| BMS-869780 Drug Profile | 37 | 1 |
| BMS-986115 Drug Profile | 38 | 1 |
| GSI-34 Drug Profile | 39 | 1 |
| LP-226A1 Drug Profile | 40 | 1 |
| MK-0752 Drug Profile | 41 | 1 |
| MRK-003 Drug Profile | 42 | 1 |
| NGP-328 Drug Profile | 43 | 1 |
| NGP-555 Drug Profile | 44 | 2 |
| NIC-515 Drug Profile | 46 | 2 |
| nirogacestat Drug Profile | 48 | 2 |
| SL-301 Drug Profile | 50 | 1 |
| SL-302 Drug Profile | 51 | 1 |
| Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease Drug Profile | 52 | 1 |
| Small Molecule Bi-functional Beta Secretase and Gamma Secretase Inhibitors for Alzheimer Disease Drug Profile | 53 | 1 |
| Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease Drug Profile | 54 | 1 |
| Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease Drug Profile | 55 | 1 |
| Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease Drug Profile | 56 | 1 |
| Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease Drug Profile | 57 | 1 |
| Small Molecules to Inhibit Ap1B Gamma-Secretase for Alzheimer's Disease Drug Profile | 58 | 1 |
| Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease Drug Profile | 59 | 1 |
| Small Molecules to Inhibit Gamma Secretase for Hearing Loss Drug Profile | 60 | 1 |
| Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss Drug Profile | 61 | 1 |
| Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease Drug Profile | 62 | 1 |
| Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease Drug Profile | 63 | 1 |
| Gamma Secretase (EC 3.4.23.46) Dormant Projects | 64 | 2 |
| Gamma Secretase (EC 3.4.23.46) Discontinued Products | 66 | 1 |
| Gamma Secretase (EC 3.4.23.46) Featured News &Press Releases | 67 | 4 |
| Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer s Disease; Reports Initial Results of Phase 1a Clinical Trial | 67 | 1 |
| Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer s Disease | 67 | 1 |
| Jun 27, 2012: Humanetics Announces Alzheimer's Disease Patent Issuance | 67 | 1 |
| Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease | 68 | 1 |
| Jul 21, 2009: Critical Outcome Technologies Inc. Announces The Launch Of A Drug Discovery Program For Alzheimer S Disease | 68 | 1 |
| Jul 12, 2009: Humanetics' Development Partner Mount Sinai Presents Phase IIA Preliminary Clinical Findings Of NIC5-15 At the Alzheimer's Association 2009 | 69 | 1 |
| Mar 30, 2006: Humanetics Corporation Announces FDA Approval Of Investigational New Drug (IND) Application For NIC5-15. | 69 | 1 |
| Dec 01, 2005: Humanetics Signs Exclusive License With Mount Sinai School Of Medicine To Develop Oral Agent NIC5-15, To Combat Alzheimer's Disease | 70 | 1 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |